Monitor the next filing or press release for details on the officer/director change and any Regulation FD disclosure content, as these could carry material information. Until specifics are released, expect minimal immediate stock movement.
Price Chart
Executive Summary
LB Pharmaceuticals Inc. filed an 8-K covering Item 5.02 (officer/director departure or appointment), Item 7.01 (Regulation FD disclosure), and Item 9.01 (exhibits). The filing is administrative in nature, with no financial statements or material quantitative data provided. No specific officer name, departure reason, or replacement was disclosed in the available content, and no forward-looking guidance or preliminary results were included.
Key Facts
- 8-K filed with items 5.02, 7.01, and 9.01
- No financial statements or exhibits with quantitative data were provided in the document content
- Item 5.02 indicates a director/officer departure or appointment, but no details on the individual or reason were disclosed
- Item 7.01 indicates a Regulation FD disclosure, but no specific content was provided
- No forward-looking guidance, preliminary results, or material financial metrics were included
Financial Impact
No dollar amounts or percentages disclosed in the filing; financial impact cannot be quantified.
Risk Factors
- Potential negative market reaction if the officer/director departure is unexpected or involves a key executive
- Regulation FD disclosure could contain material non-public information that may affect the stock once released
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-391358 |
| Document: d157620dex991.htm | 0001193125-26-391358 |
| Document: 0001193125-26-391358-index-headers.html | 0001193125-26-391358 |
| Document: 0001193125-26-391358-index.html | 0001193125-26-391358 |
| Document: 0001193125-26-391358.txt | 0001193125-26-391358 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G/A | $34.79 | awaiting T+60 | — | $38.73 (+11.33%) |
Oct 6, 2026 20d ago | EFFECT | $34.26 | awaiting T+60 | — | $38.73 (−13.05%) |
Sep 15, 2026 5w ago | 8-K | $43.04 | awaiting T+60 | — | $38.73 (−10.01%) |
Sep 3, 2026 7w ago | 8-K | $47.52 | awaiting T+60 | — | $38.73 (−18.50%) |
Aug 11, 2026 10w ago | 8-K | $45.33 | awaiting T+60 | — | $38.73 (−14.56%) |
Aug 11, 2026 10w ago | Press Release | $45.33 | awaiting T+60 | — | $38.73 (−14.56%) |
Jul 29, 2026 12w ago | 8-K | $39.00 $39.42 | ▲ +1.08% | ▼ −3.65% | $38.73 (−0.69%) |
Jul 22, 2026 13w ago | 8-K | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $38.73 (+8.06%) |
Jul 22, 2026 13w ago | Press Release | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $38.73 (+8.06%) |
Jun 10, 2026 19w ago | 8-K | $28.54 | awaiting T+60 | — | $38.73 (+35.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers